机构:[a]Department of Otolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China首都医科大学附属北京儿童医院[b]Beijing Engineering Research Center of Pediatric Surgery, Engineering and Transformation Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China首都医科大学附属北京儿童医院[c]Department of Pediatric, Beijing Tongren Hospital, Capital Medical University, Beijing, China临床科室儿科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[d]Nanjing Geneseeq Technology Inc., Nanjing, China[e]Pediatric Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China首都医科大学附属北京儿童医院[f]Department of Ophthalmology and Vision Science, Hospital for Sick Children, Toronto, Ontario, Canada
Background: Retinoblastoma is the most common intraocular cancer in children in which above 90% of bilateral cases and 10-25% of unilateral cases have germline RB1 mutations. We summarized the spectrum of RB1 germline mutations and the clinical manifestations of unilateral retinoblastomas to guide clinical treatments.Methods: Two hundred and sixty-three unrelated patients with unilateral retinoblastoma and their parents were included between February 2014 and August 2020. Next-generation sequencing and Sanger sequencing analysis of the core promoter region and exons 1-27 including flanking intronic regions of the RB1 gene were performed. If a germline mutation was identified in a retinoblastoma patient, the parental blood sample was requested to test for the identified mutation.Results: RB1 germline mutations were identified in 39/263 (14.8%) unilateral retinoblastoma patients and 11 (28.2%) had a missense mutation, 10 (25.6%) had nonsense mutations, 2 (5.1%) had frameshifts, 1 (2.6%) had synonymous mutation, and 7 (17.9%) had a large deletion, 2 (5.1%) had splice site mutations, 6 (15.4%) had variant of uncertain significance. Moreover, 27 (69.2%) of 39 patients identified RB1 mutations were predicted to have pathogenic mutation. The median age at diagnosis of patients with identified RB1 pathogenic mutations was 16.9 months and the patients with the wild-type allele was 21.1 months (P = .323).Conclusion: The rate of germline RB1 mutations is 14.8% in our cohort of unilateral retinoblastomas. The high incidence of germline mutations indicates that genetic testing and counseling for families of unilateral retinoblastoma patients would be beneficial.
基金:
This work was supported by Beijing Hospitals Authority’ Ascent Plan
(DFL20191201); Capital Funds for Health Improvement and Research
(2018-1-2091).
第一作者机构:[a]Department of Otolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[a]Department of Otolaryngology, Head and Neck Surgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China[e]Pediatric Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China[*1]Pediatric Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China[*2]Department of Otolaryngology, Head and Neck Surgery,Pediatric Oncology Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China.
推荐引用方式(GB/T 7714):
Xiaolian Fang,Jun Chen,Yizhuo Wang,et al.RB1 germline mutation spectrum and clinical features in patients with unilateral retinoblastomas.[J].OPHTHALMIC GENETICS.2021,42(5):593-599.doi:10.1080/13816810.2021.1946703.
APA:
Xiaolian Fang,Jun Chen,Yizhuo Wang,Minchao Zhao,Xin Zhang...&Brenda L. Gallie.(2021).RB1 germline mutation spectrum and clinical features in patients with unilateral retinoblastomas..OPHTHALMIC GENETICS,42,(5)
MLA:
Xiaolian Fang,et al."RB1 germline mutation spectrum and clinical features in patients with unilateral retinoblastomas.".OPHTHALMIC GENETICS 42..5(2021):593-599